Charl Van zyl

President & CEO, H Lundbeck As

Search every verified Charl Van zyl interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a January 2025 interview on the EMJ GOLD podcast, Charl van Zyl discussed Lundbeck’s strategic focus on neurological disorders with high unmet need, including rare diseases. He stated that the company’s science is "leading us towards these spaces where there is high unmet need" and that Lundbeck is "moving more to spaces where we are treating maybe 10,000 patients in the world or a few thousand patients." Van Zyl emphasized the importance of understanding disease pathobiology and designing treatments that improve upon standard of care. Van Zyl also commented on the societal perception of the pharmaceutical industry, saying, "the impact we make on society is often misunderstood and it might only be judged through the price of the medicine or the price of the Innovation but not on the value of what we bring." He noted that connecting the company’s work to its broader societal impact is part of Lundbeck’s mission. Additionally, he highlighted the role of digital health technology and real-world evidence in monitoring treatment effectiveness.